Neuropsychological Dysfunction Associated with Cancer and Cancer Therapies: a Conceptual Review of an Emerging Target

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 May 20

PMID 15150608

Citations 51

Authors

J S Wefel

A E Kayl

C A Meyers

Affiliations

Soon will be listed here.

Abstract

Neuropsychological dysfunction associated with cancer and cancer treatment is a growing concern. Methodological limitations permeate the corpus of research in this area and have limited our understanding of the multifactorial nature of this process. The following review provides a summary of the current state of knowledge and highlights future directions.

Citing Articles

Pace A, Tanzilli A, Marchioni E, Pellerino A, Tralongo A, Bini P Brain Sci. 2024; 14(11).

PMID: 39595882 PMC: 11591954. DOI: 10.3390/brainsci14111119.

Research trends on cancer neuroscience: a bibliometric and visualized analysis.

Ma X, Deng K, Sun Y, Wu M Front Neurosci. 2024; 18:1408306.

PMID: 39268034 PMC: 11390534. DOI: 10.3389/fnins.2024.1408306.

Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.

Pertz M, Schlomer S, Seidel C, Hentschel B, Loffler M, Schackert G J Neurooncol. 2023; 164(2):353-366.

PMID: 37648934 PMC: 10522752. DOI: 10.1007/s11060-023-04419-y.

Cancer neuroscience: State of the field, emerging directions.

Winkler F, Venkatesh H, Amit M, Batchelor T, Demir I, Deneen B Cell. 2023; 186(8):1689-1707.

PMID: 37059069 PMC: 10107403. DOI: 10.1016/j.cell.2023.02.002.

Effectiveness of a Computerized Home-Based Cognitive Stimulation Program for Treating Cancer-Related Cognitive Impairment.

Tapia J, Taberner-Bonastre M, Collado-Martinez D, Pouptsis A, Nunez-Abad M, Dunabeitia J Int J Environ Res Public Health. 2023; 20(6).

PMID: 36981862 PMC: 10049401. DOI: 10.3390/ijerph20064953.

References

Keime-Guibert F, Napolitano M, Delattre J . Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998; 245(11):695-708. DOI: 10.1007/s004150050271. View

Cherrier M, Asthana S, Plymate S, Baker L, Matsumoto A, Peskind E . Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001; 57(1):80-8. DOI: 10.1212/wnl.57.1.80. View

Torres I, Mundt A, Sweeney P, Llanes-Macy S, Dunaway L, Castillo M . A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology. 2003; 60(7):1113-8. DOI: 10.1212/01.wnl.0000055862.20003.4a. View

Musselman D, Lawson D, Gumnick J, Manatunga A, Penna S, Goodkin R . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13):961-6. DOI: 10.1056/NEJM200103293441303. View

Gregor A, Cull A, Traynor E, Stewart M, Lander F, Love S . Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol. 1996; 41(1):55-9. DOI: 10.1016/s0167-8140(96)91782-x. View

Meyers C, Hess K, Yung W, Levin V . Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000; 18(3):646-50. DOI: 10.1200/JCO.2000.18.3.646. View

McAllister L, Doolittle N, Guastadisegni P, Kraemer D, Lacy C, Crossen J . Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000; 46(1):51-60; discussion 60-1. View

Armstrong C, Goldstein B, Shera D, Ledakis G, Tallent E . The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer. 2003; 97(3):649-56. DOI: 10.1002/cncr.11099. View

Meyers C, Hess K . Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003; 5(2):89-95. PMC: 1920671. DOI: 10.1093/neuonc/5.2.89. View

10.

SHELINE G . Radiation therapy of brain tumors. Cancer. 1977; 39(2 Suppl):873-81. DOI: 10.1002/1097-0142(197702)39:2+<873::aid-cncr2820390725>3.0.co;2-y. View

11.

OShaughnessy J . Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2003; 3 Suppl 3:S116-20. DOI: 10.3816/cbc.2002.s.022. View

12.

Green H, Pakenham K, Headley B, Yaxley J, Nicol D, Mactaggart P . Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002; 90(4):427-32. DOI: 10.1046/j.1464-410x.2002.02917.x. View

13.

Valentine A, Meyers C, Kling M, Richelson E, Hauser P . Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25(1 Suppl 1):39-47. View

14.

McKenna S, Simon N . An assessment of agonist/antagonist effects of tamoxifen in the female mouse brain. Horm Behav. 1992; 26(4):536-44. DOI: 10.1016/0018-506x(92)90020-v. View

15.

Meyers C, Kudelka A, Conrad C, Gelke C, Grove W, Pazdur R . Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res. 1997; 3(3):419-22. View

16.

Paganini-Hill A, Clark L . Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2001; 64(2):165-76. DOI: 10.1023/a:1006426132338. View

17.

McEwen B, Alves S . Estrogen actions in the central nervous system. Endocr Rev. 1999; 20(3):279-307. DOI: 10.1210/edrv.20.3.0365. View

18.

Meyers C, Abbruzzese J . Cognitive functioning in cancer patients: effect of previous treatment. Neurology. 1992; 42(2):434-6. DOI: 10.1212/wnl.42.2.434. View

19.

Salminen E, Portin R, Korpela J, Backman H, Parvinen L, Helenius H . Androgen deprivation and cognition in prostate cancer. Br J Cancer. 2003; 89(6):971-6. PMC: 2376935. DOI: 10.1038/sj.bjc.6601235. View

20.

Vigliani M, Sichez N, Poisson M, Delattre J . A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys. 1996; 35(3):527-33. DOI: 10.1016/s0360-3016(96)80015-0. View